CLEVELAND—New research supported by Ganeden Biotech shows its patented probiotic GanedenBC30 can offer both digestive and immune health benefits to HIV patients. (AIDS Research and Human Retroviruses. 2014, Aug; Online. DOI: 10.1089/aid.2014.0181)
The study was a randomized, double-blind and placebo-controlled trial in HIV positive subjects who consumed either 2 billion CFU of GanedenBC30/d or a matching placebo for 90 days.
This study demonstrated that GanedenBC30 supports both digestive and immune health in HIV subjects, and it also provided additional evidence that in an immune-compromised subject group, there is an absence of safety concerns when consuming GanedenBC30 on a daily basis.
"HIV infection has a profound impact on the gastrointestinal immune system, which many scientists believe to be central to the development of AIDS," said Otto Yang, scientific director of the AIDS Healthcare Foundation, and professor, associate chief of infectious diseases at UCLA. “This study demonstrates that probiotics may be a means to beneficially support the GI immune system in HIV subjects."
Check out INSIDER’s Probiotic Digital Pulse to explore the expanding science supporting probiotics in a multitude of demographics—from children to the elderly.